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Low-grade spiradenocarcinoma is a rare skin tumor, with fewer than six reported cases, arising
in the context of CYLD cutaneous syndrome (CCS; syn: Brooke-Spiegler syndrome [BSS]). We
report two independent cases of spiradenocarcinoma arising in a 50-year-old man with CCS.
The tumors grew rapidly, prompting clinical excision. The histologic features in our cases corre-
sponded to the salivary gland type basal cell adenocarcinoma-like pattern, low grade (BCAC-
LG), that has been previously recognized as a recurrent finding in CCS. We performed genetic
testing of the patient and found a novel mutation in CYLD. Recognition of low-grade spiradeno-
carcinoma can be difficult for the pathologist as the features can be subtle, especially in those
cases where the transition from benign to malignant tumor is gradual. We examined p63 and
smooth muscle actin (SMA) expression patterns in BCAC-LG and compared it with the expres-
sion pattern in the precursor spiradenoma. Our report provides information on two rare tumors
in the context of CCS and suggests that the pattern of p63 and SMA staining may aid pathologi-
cal detection of the BCAC-LG subtype of spiradenocarcinoma.
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1 | INTRODUCTION
Low-grade spiradenocarcinoma is a rare skin tumor that may arise in
CYLD cutaneous syndrome (CCS). Recently, CYLD loss as a genetic
driver in inherited cylindromas and spiradenomas, associated with
increased MYB signaling, has been recognized in CCS.1 In contrast,
sporadic cutaneous cylindromas recurrently harbor MYB-NFIB fusion
transcripts2 that result in MYB overexpression. The convergence on
MYB signaling in inherited and sporadic tumors suggests that the biol-
ogy of sporadic spiradenocarcinoma may be informed by the study of
CCS patients. We report a case of two spiradenocarcinomas arising in
a 50-year-old man with CCS. The histologic features in our case corre-
sponded to the salivary gland type basal cell adenocarcinoma-like pat-
tern, low grade (BCAC-LG), a type previously recognized as
predominating in CCS. Recognition of BCAC-LG spiradenocarcinoma
can be difficult in routine practice as the features can be subtle and
easily missed, especially in those cases where the transition from
benign to malignant tumor is gradual. We examined the expression
pattern of p63 and smooth muscle actin (SMA) in our two cases of
BCAC-LG spiradenocarcinoma and suggest that these immunohisto-
chemical markers may aid in the distinction of BCAC-LG spiradenocar-
cinoma from spiradenoma in CCS.
2 | CASE REPORT
A 50-year-old male presented with a rapidly enlarging lesion on his
back. He had multiple skin lesions affecting most of his upper body,
arms, and face (Figure 1A). The patient had first noticed skin tumors
around the age of 18 years, and had multiple lesions removed, which
were confirmed as cylindromas and spiradenomas. He was severely
affected with multiple scalp tumors, such that he underwent total
scalp excision with skin grafting. He had affected relatives, and
sequencing of the CYLD gene in peripheral lymphocyte DNA
revealed a novel pathogenic heterozygous truncating mutation
(c.2476C>T; p.Gln823*) (Figure 1B), consistent with a diagnosis ofNeil Rajan and Lucy Melly contributed equally to this study.
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CCS. The patient underwent surgical excision of the lesion on the
back, which showed low-grade spiradenocarcinoma. Two years after
this a further enlarging tumor was excised from his suprapubic skin
and confirmed to be a primary spiradenocarcinoma. Five years since
his first spiradenocarcinoma, neither lesion has recurred.
Histopathology of the tumor from his back showed an ulcerated
spiradenocarcinoma arising in a spiradenoma. The spiradenocarcinoma
was characterized by increased cellularity and absence of the dual cell
population seen in spiradenoma. The neoplastic cells were arranged in
nodules and had minimal cytoplasm, and some showed a slightly spin-
dled morphology (Figure 2A,B). The ductal structures (highlighted by
carcinoma embryonic artigen staining; data not shown) appeared com-
pressed and pushed to the periphery. There was loss of the diffuse
infiltrate of small lymphocytes. Within the neoplastic nodules, the cells
showed increased mitotic activity (15/10 hpf ). The spiradenoma in
comparison was characterized by a dual population of cells arranged
in trabeculae. The cells were a mixture of small basaloid cells with
small dark nuclei, and a second cell type with a larger more irregular
vesicular nucleus and more cytoplasm. Mitotic activity was very low in
the benign component (1/10 hpf ).
Immunohistochemistry for p63 and SMA was performed on spira-
denoma and spiradenocarcinoma. p63 showed strongly positive cells
closely associated with occasional weak p63 staining cells in spirade-
noma and showed uniform but weak p63 staining in spiradenocarci-
noma (Figure 3A,B). SMA showed a mixture of SMA positive cells and
SMA negative cells diffusely throughout the lesion in spiradenoma,
and nodules of SMA negative cells with SMA positive cells com-
pressed at the periphery in spiradenocarcinoma (Figure 4A-C). These
nodules were most easily recognized on low power magnification
(Figure 4A). Similar features were seen in the spiradenocarcinoma aris-
ing in the suprapubic skin.
3 | DISCUSSION
Spiradenocarcinoma is a rare dermal appendage tumor, with approxi-
mately 100 cases reported in the literature. There is no sex predomi-
nance, and the age range is 30 to 92 years, with an average age of
59 years.3 Kazakov et al reported 24 cases of malignant neoplasms
arising in pre-existing spiradenoma, cylindroma, and spiradenocylin-
droma and importantly included five cases arising in CCS.4 Kazakov
et al suggested classifying spiradenocarcinoma into four histological
subtypes, namely: salivary gland type basal cell adenocarcinoma-like
pattern, low grade (BCAC-LG); salivary gland type basal cell
adenocarcinoma-like pattern, high grade (BCAC-HG); invasive adeno-
carcinoma not otherwise specified (IAC-NOS); sarcomatoid (metaplas-
tic) carcinoma. The BCAC-LG and BCAC-HG patterns relate to those
described in Granter's description5 where in the low-grade spiradeno-
carcinomas, the transition between malignant and pre-existing benign
cells is gradual, whereas in the high-grade spiradenocarcinomas, it is
abrupt. Both patterns showed loss of the dual cell population and lym-
phoid infiltrate. Of the five malignant tumors arising in CCS, three had
BCAC-LG, and two BCAC-HG.4 Recently a review of 19 cases of
BCAC-LG (1 case in the context of CCS), the pattern most often
reported in CCS, showed a relatively indolent course, characterized by
local recurrence.6 We add to the six reported cases of BCAC-LG
FIGURE 1 A, Clinical image of patient with malignant
spiradenocarcinoma arrowed (white arrow). Note the intact epidermis
and the lack of blue regions within the nodule. B, A novel
heterozygous germline mutation in CYLD
FIGURE 2 H+E (A, ×20) Low-grade spiradenocarcinoma showing
nodular growth pattern and lack of infiltrative growth. (B, ×200)
showing the lack of a dual cell population. Mitotic figures within the
malignant component are shown in the inset (×400). Scale bars
indicate 100 μm
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arising in the context of CCS,4,6 with two additional cases arising in a
genotyped patient with a novel CYLD mutation.
CCS is an inherited autosomal dominant disease with variable
expression and incomplete penetrance.7 It results in the growth of
multiple adnexal neoplasms from the follicular-sebaceous-apocrine
unit especially trichoepitheliomas, cylindromas, spiradenomas, and
spiradenocylindroma. The presence of multiple such tumors or a fam-
ily history allows for clinical diagnosis. CCS can present in any of three
patterns, namely familial cylindromatosis (FC) where the predominant
tumors are scalp cylindromas, multiple familial trichoepitheliomas,
where the predominant tumors are facial trichoepitheliomas, and
Brooke-Spiegler syndrome (BSS), where any combination of trichoe-
pitheliomas, cylindromas and related spiradenomas are seen.7 Genetic
diagnosis as performed in our case is now possible and aids broader
issues such as genetic counseling of the patient's family. CYLD is a
tumor suppressor gene that plays a regulatory role in immunity, devel-
opment, inflammation, and lipid metabolism. There are more than
110 known mutations in CYLD, and the majority are truncating muta-
tions resulting predicted loss of function, although splice site and mis-
sense mutations are also seen.7,8 It is striking that two primary low-
grade spiradenocarcinoma arose in our case when the patient was
50 and 52 years of age. Taken together with the cases reported
previously,4 low-grade spiradenocarcinoma appears to develop in
older patients with CCS, with the range of reported ages at presenta-
tion of seven cases ranging from 43 to 72 years.
We suggest that p63 and SMA immunohistochemistry may assist
histologic detection of the BCAC-LG subtype of spiradenocarcinoma.
Further studies are needed to fully assess the usefulness of p63 and
SMA in this context. Brenn et al highlight the consistent reduction or
loss of MYB expression as a useful marker of low-grade spiradenocar-
cinoma when compared to the benign component it has arisen from.6
p53 expression and Ki-67 by contrast were of limited use in
FIGURE 3 p63 (A, ×200) staining in low-grade spiradenocarcinoma of
the trunk, showing uniform weak p63 staining, with some p63
negative cells. (B, ×200) Benign precursor spiradenoma showing a
majority of strong nuclear p63 staining and occasional weak and
negative p63 staining cells. Scale bars indicate 100 μm
FIGURE 4 Smooth muscle actin (SMA) (A, ×40) staining showing the
nodules of SMA negative cells in spiradenocarcinoma. (B, ×200) SMA
staining pattern in benign spiradenoma component and (C, ×200)
malignant spiradenocarcinoma. Scale bars indicate 100 μm
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discriminating malignant components due to variability of expression
across the cases assessed. p63 expression has been described in a sin-
gle case of sporadic BCAC-LG spiradenocarcinoma.9 The authors
showed a difference in staining between benign and malignant com-
ponents, compatible with our findings. We provide additional data on
the pattern and intensity of p63 and SMA expression in CCS, suggest-
ing that these markers may aid the histopathologic recognition of
BCAC-LG spiradenocarcinoma. Taken together with the morphologi-
cal features seen in BCAC-LG type spiradenocarcinoma, these immu-
nohistochemical markers may aid diagnosis; however, further studies
in a large series are important to confirm this impression.
In summary, we present a patient with two cases of spiradenocar-
cinoma, arising in a setting of CCS. Subclassification of subtypes
appears to be important, as it has been suggested that the histology
influences prognosis. Our follow-up data is supportive of the relative
indolent clinical course BCAC-LG type spiradenocarcinoma in CCS has
been noted to have, and this may influence the clinical management
of these rare patients.
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